{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:22:27Z","timestamp":1783970547066,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijcard.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T21:21:27Z","timestamp":1520457687000},"page":"344-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction"],"prefix":"10.1016","volume":"257","author":[{"given":"Ales","family":"Linhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.01.006_bb0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/jhh.2011.56","article-title":"Geographic variation in left ventricular mass and mass index: a systematic review","volume":"26","author":"Poppe","year":"2012","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/jhh.2009.16","article-title":"Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?","volume":"23","author":"Cuspidi","year":"2009","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10554-010-9584-5","article-title":"Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification","volume":"26","author":"Brumback","year":"2010","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/heart.83.6.667","article-title":"Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe","volume":"83","author":"Kampmann","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0030","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00246-016-1380-0","article-title":"The prevalence of left ventricular hypertrophy in obese children varies depending on the method utilized to determine left ventricular mass","volume":"37","author":"Mahgerefteh","year":"2016","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0035","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0040","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.003454","article-title":"Clinical profile of athletes with hypertrophic cardiomyopathy","volume":"8","author":"Sheikh","year":"2015","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0050","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.amjcard.2014.07.070","article-title":"Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy","volume":"114","author":"Caselli","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/hrt.2003.031161","article-title":"Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy","volume":"91","author":"Thaman","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","article-title":"Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging","volume":"5","author":"Olivotto","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ijcard.2014.11.014","article-title":"Cardiac manifestations of primary mitochondrial disorders","volume":"177","author":"Finsterer","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2009.371","article-title":"Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy","volume":"301","author":"Maron","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0080","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0735-1097(99)00396-4","article-title":"Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective randomized study evaluating regression of ventricular enlargement","volume":"34","author":"Palmieri","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0090","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.amjcard.2014.07.070","article-title":"Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy","volume":"114","author":"Caselli","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/heart.87.3.247","article-title":"Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity","volume":"87","author":"Matsumura","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.amjcard.2011.03.092","article-title":"Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis","volume":"108","author":"Liu","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0105","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0125","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.amjcard.2009.10.056","article-title":"PQ interval in patients with Fabry disease","volume":"105","author":"Namdar","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0140","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/hrt.51.6.658","article-title":"Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy","volume":"51","author":"Eriksson","year":"1984","journal-title":"Br. Heart J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0145","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"O'Mahony","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0150","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0155","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacc.2011.03.020","article-title":"Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease","volume":"58","author":"Calcagnino","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0165","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ejechocard\/jer112","article-title":"The endocardial binary appearance (\u2018binary sign\u2019) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy","volume":"12","author":"Mundigler","year":"2011","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0170","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2008.02.046","article-title":"The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy","volume":"51","author":"Kounas","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0175","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1540-8175.1991.tb01395.x","article-title":"Two-dimensional echocardiography in myocardial amyloidosis","volume":"8","author":"Picano","year":"1991","journal-title":"Echocardiography"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0185","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0190","doi-asserted-by":"crossref","DOI":"10.1067\/mhj.2001.112088","article-title":"The emerging concept of mitochondrial cardiomyopathies","volume":"141","author":"Santorelli","year":"2001","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1148\/radiol.14131626","article-title":"MR imaging in hypertrophic cardiomyopathy: from magnet to bedside","volume":"273","author":"Bogaert","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.ijcard.2018.01.006_bb0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1253\/circj.CJ-15-0054","article-title":"Myocardial T1 mapping","volume":"79","author":"Bulluck","year":"2015","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0205","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1007\/s12410-014-9287-8","article-title":"T1 mapping for characterization of intracellular and extracellular myocardial diseases in heart failure","volume":"7","author":"Maestrini","year":"2014","journal-title":"Curr. Cardiovasc. Imaging Rep."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10741-014-9463-6","article-title":"Nuclear imaging for cardiac amyloidosis","volume":"20","author":"Noordzij","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0215","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","article-title":"Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies","volume":"34","author":"Aerts","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2018.01.006_bb0225","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/eurheartj\/ehq271","article-title":"Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"31","author":"Charron","year":"2010","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317362526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317362526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T05:00:31Z","timestamp":1530680431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317362526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":45,"alternative-id":["S0167527317362526"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.006","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}